Hanmi Science announced on April 25 that its consolidated operating profit for the first quarter of this year was provisionally estimated at 27.1 billion won.
This represents a decrease of 27.4% compared to the same period last year, while sales increased by 3.8% year-on-year to 332.2 billion won. Net profit fell by 21.3% to 24.5 billion won.
Hanmi Science stated, "Although both operating profit and net profit decreased, the company continues to achieve stable growth as the overall normalization of the company leads to sustained performance in the pharmaceutical distribution and healthcare business sectors." The company added, "We will pursue mid- to long-term new investments and seek future-oriented new business opportunities to improve our performance."
Specific details regarding the decrease in operating profit and other matters are expected to be confirmed after each affiliate announces its earnings. The results for Hanmi Pharm, the core business subsidiary, will be announced on April 29.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
